After US Woes, Akebia Celebrates EU Nod For Vafseo
Recommended For Anemia Associated With Kidney Disease
The US biotech is in the throes of an appeal to the FDA against the rejection of its HIF-PH inhibitor but regulators in the EU have looked more kindly on vadadustat, which will be sold as Vafseo.
